期刊文献+

HER-2阳性浸润性乳腺癌患者MRI影像多参数特征分析 被引量:2

Multi-Parameter Analysis of MRI Images in Patients with Invasive Breast Cancer with Positive HER-2
下载PDF
导出
摘要 目的探讨HER-2阳性乳腺癌患者MRI影像多参数的特征。方法回顾性分析2019年1月至2020年11月我院经病理证实的52例浸润性乳腺癌患者的MRI影像资料,分析52例患者MRI图像征象(分叶、坏死、毛刺、强化特征)、定量参数(DWI-ADC值及IVIM-DWI(D值、D^(*)值及f值))之间的差异。结果其中HER-2阳性者18例(34.6%),HER-2阴性者34例(65.4%),HER-2阳性与HER-2阴性患者肿块MRI图像特征、D值及f值差异均无统计学意义(P>0.05);HER-2阳性患者ADC值(1.11±0.193)mm^(2)/s明显高于HER-2阴性患者ADC值(0.95±0.192)mm^(2)/s,差异有统计学意义(P<0.05);HER-2阳性患者D^(*)值(4.94±1.21)mm^(2)/s明显高于HER-2阴性患者D^(*)值(3.85±1.42)mm^(2)/s,差异有统计学意义(P<0.05)。结论MRI影像定量参数ADC值及D^(*)值与HER-2阳性表达有关。 Objective To investigate the characteristics of Multi-parameter in MRI images of breast cancer patients with positive HER-2.Methods MRI imaging data of 52 patients with invasive breast cancer confirmed by pathology in our hospital from January 2019 to November 2020 were retrospectively analyzed,And the differences between MRI image signs(lobulation,necrosis,burr and enhancement features)and quantitative parameters(DWI-ADC value and IVIM-DWI(D value,D^(*)value and F value)of 52 patients were analyzed.Results Among them,18 patients(34.6%)were HER-2 positive,and 34 patients(65.4%)were HER-2 negative.There was no significant difference in MRI image signs、D value and f value between HER-2 positive and HER-2 negative patients(P>0.05).ADC value of HER-2 positive patients(1.11±0.193)mm^(2)/s was significantly higher than that of HER-2 negative patients(0.95±0.192)mm^(2)/s,the difference was statistically significant(P<0.05).The D^(*)value of HER-2 positive patients(4.94±1.21)mm^(2)/s was significantly higher than that of HER-2 negative patients(3.85±1.42)mm^(2)/s,the difference was statistically significant(P<0.05).Conclusion MRI imaging quantitative parameters ADC value and D^(*)value are related to the positive expression of HER-2.
作者 纵然 杨丽萍 束宏敏 李小虎 邓克学 ZONG Ran;YANG Li-ping;SHU Hong-min;LI Xiao-hu;DENG Ke-xue(Department of Radiology of The First Affiliated Hospital of USTC,Division of Life Science and Technology of China,Hefei 230036,Anhui Province,China;Department of Radiology,the First Affiliated Hosptial of Anhui Medical University,Hefei 230036,Anhui Province,China)
出处 《中国CT和MRI杂志》 2023年第6期81-82,92,共3页 Chinese Journal of CT and MRI
关键词 浸润性乳腺癌 HER-2阳性 DWI IVIMDWI Invasive Breast Cancer HER-2 Positive DWI IVIM
  • 相关文献

参考文献10

二级参考文献121

  • 1张瑰红,施达仁,梁晓曼,侯景辉,康苏娅,朱卫东,李晓兵,邵云,陈丽荣,周燕.显色原位杂交和免疫组织化学检测乳腺癌HER2/neu基因状况和蛋白表达的对照性研究[J].中华病理学杂志,2006,35(10):580-583. 被引量:29
  • 2<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量:164
  • 3步宏,郑杰.美国临床肿瘤学会/美国病理学医师学院乳腺癌HER2检测指南简介[J].中华病理学杂志,2007,36(7):496-497. 被引量:24
  • 4Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer [ J]. J Clin Oncol, 2007, 25 (33) :5287-5312.
  • 5Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Chnical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer[ Jl. J Clin Oncol, 2007, 25 ( 1 ) : 118- 145.
  • 6Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth faetor reeeptor 2 testing in breast eaneer: American Society of Clinical Oneology/College of American Pathologists clinical practice guideline update[J]. J Clin Oneol, 2013, 31 (31) :3997-4013.
  • 7Hanna WM, Kwok K. Chromogenic in-situ hybridization:a viable ahernative to fluorescence in-situ hybridization in the HER2 testing algorithm[J]. Mod Pathol, 2006, 19(4) :481-487.
  • 8Park K, Han S, Kim JY, et al. Silver-enhanced in situ hybridization as an alternative to fluorescence in situ hybridization for assaying HER2 amplification in clinical breast cancer [ J ]. J Breast Cancer, 2011, 14(4) :276-282.
  • 9Haines GK 3rd, Wiley E, Susnik B, et al. HER2 in well differentiated breast cancer: is testing necessary? [ J ]. Breast Cancer Res Treat, 2008, 112(3) :551-556.
  • 10Zhu X, Lu Y, Lu H, et al. Genetic alterations and protein expression of HER2 and chromosome 17 polysomy in breast cancer [J]. Hum Pathol, 2011,42(10) : 1499-1504.

共引文献365

同被引文献23

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部